Supplementary Online Content


eAppendix A1. Study design

eAppendix A2. Interaction Test

This supplementary material has been provided by the authors to give readers additional information about their work.
Appendix A1

First randomization

Arm A
- non progressive

Arm B
- non progressive

Second randomization

Arm A1
- non progressive

Arm A2
- non progressive

Arm B1
- non progressive

Arm B2
- non progressive

EVALUATION: non progressive

EVALUATION: non progressive

Until progressive disease

EVALUATION: non progressive

EVALUATION: non progressive

At progression further treatment is at investigator discretion. Surgical resection can be considered at any evaluation.

Gemcitabine 1000 mg/m² intravenous infusion over 30 minutes once weekly for 3 weeks

capcitabine
irradiation

Erlotinib
- 100 mg/day

Erlotinib
- 150 mg/day

© 2016 American Medical Association. All rights reserved.
Overall Survival Probability

- Gemcitabine/Chemotherapy: n=68, n.events=56, median time=18 months
- Gemcitabine/Chemoradiotherapy: n=67, n.events=52, median time=16.7 months
- Gemcitabine + Erlotinib/Chemotherapy: n=68, n.events=56, median time=14.5 months
- Gemcitabine + Erlotinib/Chemoradiotherapy: n=66, n.events=57, median time=14.7 months

Log-rank p=0.238

**Time since the first randomization (months)**

**Overall Survival Probability**

- Gemcitabine/Chemotherapy: n=68, n.events=56, median time=18 months
- Gemcitabine/Chemoradiotherapy: n=67, n.events=52, median time=16.7 months
- Gemcitabine + Erlotinib/Chemotherapy: n=68, n.events=56, median time=14.5 months
- Gemcitabine + Erlotinib/Chemoradiotherapy: n=66, n.events=57, median time=14.7 months

Log-rank p=0.238